A Phase 1, Open-Label Study in Healthy Volunteers to Evaluate the Relative Bioavailability of NX-5948 Tablets Compared to Capsules, and the Effect of Food and an Acid-reducing Agent on the Pharmacokinetics of NX-5948
Latest Information Update: 26 Dec 2024
Price :
$35 *
At a glance
- Drugs Esomeprazole (Primary) ; NX-5948 (Primary) ; NX-5948
- Indications Autoimmune disorders; Chronic lymphocytic leukaemia; Diffuse large B cell lymphoma; Follicular lymphoma; Lymphoma; Mantle-cell lymphoma; Marginal zone B-cell lymphoma; Non-Hodgkin's lymphoma; Rhabdomyosarcoma; Rheumatoid arthritis; Waldenstrom's macroglobulinaemia
- Focus Pharmacokinetics
- Sponsors Nurix
- 10 Dec 2024 New trial record